PBX1 (PBX Homeobox 1)

PBX1 overexpression reversed these effects, reduced MeHg-induced DNA damage, and enhanced BRCA1 promoter activity. Collectively, PBX1 attenuates MeHg-induced apoptosis in SH-SY5Y cells by inhibiting ROS accumulation, reducing DSBs, and enhancing HR repair, likely via BRCA1 activation.

P1/2, N=20, Recruiting, University Hospital Tuebingen | Trial completion date: Mar 2027 --> Feb 2029 | Trial primary completion date: Mar 2027 --> Jul 2028

Moreover, we elucidated the molecular mechanism through which the pre-B-cell leukemia transcription factor 1-insulin receptor substrate 1 signaling axis sustains metabolic homeostasis. Furthermore, we demonstrated that the blood-brain barrier-permeable trans-activator of transcription-pre-B-cell leukemia transcription factor 1 fusion protein constitutes a mechanistically innovative and highly translatable therapeutic strategy for Alzheimer's disease.

PBX1-mediated AP1M2 facilitates cell proliferation, migration, invasion, and docetaxel resistance to accelerate TNBC malignant behavior, providing a novel target for TNBC treatment.

Furthermore, patients with TCF3::PBX1 or MEF2D fusion and high EVI1 expression had RFS and OS similar to those without the corresponding fusions, and patients with ZNF384 fusion and low EVI1 expression had RFS and OS comparable to those without ZNF384 fusions (all p > 0.05). Low EVI1 transcript levels at diagnosis are related to poor prognosis in adult Ph-negative B-ALL, and EVI1 expression may improve fusion gene-defined risk stratification.

These results establish Pbx1 as a key mediator of HC aging and a promising therapeutic target for ARHL. Our findings demonstrate that AAV-mediated Pbx1 overexpression represents a potential therapeutic approach to prevent ARHL progression, paving the way for future clinical management of this prevalent sensory disorder.

Molecular and cytogenetics study revealed a t(1;22) resulting in an EWSR1::PBX1 fusion. This case highlights diagnostic and prognostic implications of this recently recognized distinct EWSR1 entity.

The high diagnostic coverage and rapid turnaround of the FISH-based approach underscore its value as a reliable and efficient diagnostic tool in newly diagnosed ALL. The authors have confirmed clinical trial registration is not needed for this submission.

FET-rearranged MET are epigenetically unrelated to cutaneous and salivary gland MET, and their malignant counterparts are best classified as sarcomas rather than carcinomas.

P1/2, N=32, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Mar 2027

GSDME is potentially associated with the ETS transcription factor ELF3 and the Homeobox transcription factor PBX1. The reduced expression of CK13 and CK19 in the GSDME-overexpressing group may serve as a potential mechanism by which GSDME inhibits HNSCC growth.

In conclusion, we identified a novel de novo heterozygous missense variant in PBX1 that impairs nuclear localization of the protein, potentially limiting its role as a TF and possibly explaining the clinical phenotype of the patient.